Amedisys Inc (AMED) Director Bruce D. Perkins Buys 2,500 Shares

Share on StockTwits

Amedisys Inc (NASDAQ:AMED) Director Bruce D. Perkins acquired 2,500 shares of the company’s stock in a transaction dated Wednesday, May 15th. The stock was acquired at an average price of $111.84 per share, with a total value of $279,600.00. Following the purchase, the director now owns 22,088 shares in the company, valued at approximately $2,470,321.92. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Shares of Amedisys stock opened at $108.34 on Friday. The stock has a market cap of $3.47 billion, a P/E ratio of 29.85, a PEG ratio of 1.35 and a beta of 1.33. The company has a quick ratio of 0.91, a current ratio of 0.91 and a debt-to-equity ratio of 0.69. Amedisys Inc has a 12-month low of $71.74 and a 12-month high of $140.91.

Amedisys (NASDAQ:AMED) last announced its earnings results on Tuesday, April 30th. The health services provider reported $1.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.89 by $0.22. The business had revenue of $467.34 million during the quarter, compared to analysts’ expectations of $460.83 million. Amedisys had a net margin of 7.14% and a return on equity of 28.25%. The firm’s revenue for the quarter was up 17.0% on a year-over-year basis. During the same quarter last year, the company posted $0.79 EPS. As a group, equities research analysts forecast that Amedisys Inc will post 4.08 EPS for the current fiscal year.

A number of equities analysts have recently issued reports on the stock. BidaskClub cut shares of Amedisys from a “hold” rating to a “sell” rating in a research note on Friday. ValuEngine cut shares of Amedisys from a “buy” rating to a “hold” rating in a research report on Tuesday, May 14th. Zacks Investment Research upgraded shares of Amedisys from a “hold” rating to a “buy” rating and set a $151.00 target price for the company in a research report on Thursday, February 7th. Craig Hallum dropped their target price on shares of Amedisys from $132.00 to $124.00 and set a “hold” rating for the company in a research report on Friday, March 1st. They noted that the move was a valuation call. Finally, Raymond James upgraded shares of Amedisys from a “market perform” rating to an “outperform” rating and set a $140.00 target price for the company in a research report on Thursday, May 2nd. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $125.90.

Several institutional investors have recently made changes to their positions in AMED. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Amedisys by 15.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,900 shares of the health services provider’s stock valued at $223,000 after acquiring an additional 251 shares in the last quarter. Rhumbline Advisers increased its position in Amedisys by 20.4% in the 4th quarter. Rhumbline Advisers now owns 79,058 shares of the health services provider’s stock valued at $9,258,000 after acquiring an additional 13,414 shares in the last quarter. Assenagon Asset Management S.A. increased its position in Amedisys by 146.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 49,306 shares of the health services provider’s stock valued at $5,774,000 after acquiring an additional 29,262 shares in the last quarter. Martingale Asset Management L P increased its position in Amedisys by 12.2% in the 4th quarter. Martingale Asset Management L P now owns 23,006 shares of the health services provider’s stock valued at $2,695,000 after acquiring an additional 2,500 shares in the last quarter. Finally, Vanguard Group Inc increased its position in Amedisys by 14.3% in the 3rd quarter. Vanguard Group Inc now owns 3,326,180 shares of the health services provider’s stock valued at $415,640,000 after acquiring an additional 415,060 shares in the last quarter. Institutional investors and hedge funds own 91.71% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was published by Week Herald and is the property of of Week Herald. If you are accessing this report on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The original version of this report can be read at https://weekherald.com/2019/05/19/amedisys-inc-amed-director-bruce-d-perkins-buys-2500-shares.html.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Recommended Story: Balanced Fund

Insider Buying and Selling by Quarter for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.